Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.48 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 5/20 | 0.37 |
| ▸ | MAOB | P27338 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | HMGCR | P04035 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22694182 | 0.85 | CYP3A4 (0.47) | PTGS1PTGS2CYP1A2CYP2C9ALOX5 | |
| SCHEMBL22694189 | 0.85 | CYP3A4 (0.45) | PTGS1PTGS2CYP1A2CYP2C9ALOX5 | |
| SCHEMBL22694220 | 0.83 | ALOX5 (0.52) | PTGS1PTGS2CYP1A2CYP2C9ALOX5 | |
| SCHEMBL22694228 | 0.80 | LMNA (0.40) | GABBR2GABBR1GPR55PTGS1PTGS2 | |
| SCHEMBL22694183 | 0.80 | CA12 (0.47) | PTGS2MAOBCYP2C9 | |
| SCHEMBL22694187 | 0.80 | AKR1B10 (0.48) | MAOAMAOB | |
| SCHEMBL22694185 | 0.78 | SNCA (0.41) | PTGS1PTGS2MAOBCYP1A2CYP2C9 | |
| SCHEMBL22694184 | 0.78 | AKR1B10 (0.30) | — | |
| SCHEMBL22694186 | 0.77 | EPHX2 (0.57) | PTGS1PTGS2NPSR1MAOAMAOB | |
| SCHEMBL19961454 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369605-A1 | ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369605-A1 | ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | PAG1, SLC6A5, LBR | GABBR2 1211/4885GABBR1 1218/4885GPR55 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.